CL2004000512A1 - Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes - Google Patents

Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes

Info

Publication number
CL2004000512A1
CL2004000512A1 CL200400512A CL2004000512A CL2004000512A1 CL 2004000512 A1 CL2004000512 A1 CL 2004000512A1 CL 200400512 A CL200400512 A CL 200400512A CL 2004000512 A CL2004000512 A CL 2004000512A CL 2004000512 A1 CL2004000512 A1 CL 2004000512A1
Authority
CL
Chile
Prior art keywords
propilcarbamoil
benzotiazol
propanoic
inhibitors
diabetes
Prior art date
Application number
CL200400512A
Other languages
English (en)
Inventor
Hepworth David
Original Assignee
Pfizer Inc Sa Organizada Bajo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305916A external-priority patent/GB0305916D0/en
Priority claimed from GB0329143A external-priority patent/GB0329143D0/en
Application filed by Pfizer Inc Sa Organizada Bajo filed Critical Pfizer Inc Sa Organizada Bajo
Publication of CL2004000512A1 publication Critical patent/CL2004000512A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

DERIVADOS DEL ACIDO 3-(1-(3-(1,3-BENZOTIAZOL-6-IL)PROPILCARBAMOIL)PROPANOICO INHIBIDORES DE LA ENZIMA ENDOPEPTIDASA NEUTRA (NEP) Y SUS USOS EN EL TRATAMIENTO DE LA DISFUNCION SEXUAL MASCULINA Y FEMENINA, PARTICULARMENTE DE LA DISFUNCION SEXUAL FEMENINA (FSD) ESPECIALMENTE CUANDO LA FSD ES UN TRANSTORNO DE EXCITACION SEXUAL FEMENINA (FSDA)
CL200400512A 2003-03-14 2004-03-12 Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes CL2004000512A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305916A GB0305916D0 (en) 2003-03-14 2003-03-14 New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
GB0329143A GB0329143D0 (en) 2003-12-16 2003-12-16 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
CL2004000512A1 true CL2004000512A1 (es) 2005-01-21

Family

ID=32992599

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400512A CL2004000512A1 (es) 2003-03-14 2004-03-12 Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes

Country Status (25)

Country Link
US (1) US20040180941A1 (es)
EP (1) EP1606272A1 (es)
JP (1) JP3923512B2 (es)
KR (1) KR20050110003A (es)
AP (1) AP2005003393A0 (es)
AR (1) AR043551A1 (es)
AU (1) AU2004220269A1 (es)
BR (1) BRPI0408377A (es)
CA (1) CA2519072A1 (es)
CL (1) CL2004000512A1 (es)
EA (1) EA200501204A1 (es)
EC (1) ECSP056017A (es)
HR (1) HRP20050797A2 (es)
IS (1) IS8003A (es)
MA (1) MA27720A1 (es)
MX (1) MXPA05009788A (es)
NL (1) NL1025709C2 (es)
NO (1) NO20054169L (es)
OA (1) OA13039A (es)
PA (1) PA8597401A1 (es)
PE (1) PE20050310A1 (es)
TN (1) TNSN05227A1 (es)
TW (1) TW200504038A (es)
UY (1) UY28226A1 (es)
WO (1) WO2004080985A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020291A2 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
WO2006027680A1 (en) * 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
CN102861019B (zh) 2004-12-24 2016-05-25 诺华股份有限公司 治疗或预防神经性疼痛的药物
WO2007016361A2 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
EP2952185A1 (en) * 2006-03-20 2015-12-09 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis of inflammatory pain
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
KR101177866B1 (ko) 2011-03-24 2012-08-28 주식회사 케이엠더블유 케이블 접속 장치
US20190385720A1 (en) * 2018-06-14 2019-12-19 AstraZeneca UK Litimited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
AU2019287546A1 (en) * 2018-06-14 2021-01-21 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition
IL281770B2 (en) 2018-09-25 2025-03-01 Antabio Sas Indane derivatives for use in the treatment of bacterial infection
AU2020377914A1 (en) * 2019-11-08 2022-06-02 Vella Bioscience, Inc. Peripherally acting cannabidiol(CBD)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
GB202402524D0 (en) * 2024-02-22 2024-04-10 Futura Medical Developments Ltd Topical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US2599000A (en) * 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
NL175059C (nl) * 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3528032A1 (de) * 1985-08-05 1987-02-05 Hoechst Ag Verfahren zur herstellung 2-substituierter benzthiazole
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU4844396A (en) * 1995-03-01 1996-09-18 Kyowa Hakko Kogyo Co. Ltd. Imidazoquinazoline derivatives
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
HRP20030751A2 (en) * 2001-03-28 2005-08-31 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

Also Published As

Publication number Publication date
US20040180941A1 (en) 2004-09-16
NO20054169L (no) 2005-12-07
OA13039A (en) 2006-11-10
TNSN05227A1 (fr) 2007-06-11
CA2519072A1 (en) 2004-09-23
WO2004080985A1 (en) 2004-09-23
NL1025709A1 (nl) 2004-09-16
AR043551A1 (es) 2005-08-03
EA200501204A1 (ru) 2006-06-30
KR20050110003A (ko) 2005-11-22
AP2005003393A0 (en) 2005-09-30
UY28226A1 (es) 2004-11-08
TW200504038A (en) 2005-02-01
PE20050310A1 (es) 2005-05-04
NO20054169D0 (no) 2005-09-07
AU2004220269A1 (en) 2004-09-23
BRPI0408377A (pt) 2006-03-21
JP3923512B2 (ja) 2007-06-06
JP2006526572A (ja) 2006-11-24
ECSP056017A (es) 2006-01-27
EP1606272A1 (en) 2005-12-21
PA8597401A1 (es) 2005-05-24
MXPA05009788A (es) 2005-10-26
HRP20050797A2 (en) 2006-02-28
NL1025709C2 (nl) 2005-03-14
IS8003A (is) 2005-08-29
MA27720A1 (fr) 2006-01-02

Similar Documents

Publication Publication Date Title
CL2004000512A1 (es) Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
GT200500354A (es) Metodo para preparar n-fenilpirazol-1-carboxamidas
NI200800227A (es) Acidos 1,3-dioxano carboxilicos
AR091405A2 (es) Omega-carboxiaril difenil urea sustituida con fluoro y composiciones farmaceuticas que las contienen
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
ECSP055853A (es) Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
CL2004000293A1 (es) Compuestos derivados de dihidrofenantridin-sulfonamidas sustituidas, sus sales; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y su uso en el tratamiento de la diabetes tipo ii, alzheimer, demencia senil, asma, col
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
CL2009001214A1 (es) Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
ECSP077271A (es) Derivados de pirimidina
ECSP056071A (es) Nueva difenilazetidinona con características fisiológicas mejoradas, correspondiente método de producción, medicamentos que contienen dicho compuesto y su uso
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
BR0207168A (pt) Composição de limpeza lìquida aquosa, método para limpeza de um substrato, e, uso de uma substância orgânica que forma um complexo com um metal de transição
ECSP077259A (es) Derivados de pirimidina
BRPI0409454A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização
GT200500257AA (es) Procedimiento para producir derivados de amina opticamente activos
BR0309575A (pt) Processo para a preparação de uma solução aquosa de acrilato de metal alcalino, e, uso de uma solução aquosa de acrilato de metal alcalino
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
ES2526912T3 (es) Composición farmacéutica que contiene neurotoxina botulínica A2
AR039937A1 (es) Derivados de azetidina como inhibidores de tripsina proteasas